TScan Therapeutics, Inc. Common Stock
TCRXTScan Therapeutics, Inc. (TCRX) is a biotechnology company focused on developing adoptive T cell therapies for cancer treatment. Utilizing its proprietary TCR-T platform, TScan aims to engineer T cells that target specific tumor-associated antigens, with the goal of creating personalized and effective immunotherapies for solid tumors. Founded to advance T cell-based cancer treatments, TScan combines advanced science with innovative technology to address unmet needs in oncology.
Company News
TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
TScan Therapeutics will present two abstracts at the ACR Convergence 2025, highlighting novel discoveries in T cell targets for autoimmune disorders like Ankylosing Spondylitis and Scleroderma using their TargetScan technology.
TScan Therapeutics, a clinical-stage biotech company, announced participation in upcoming investor conferences and provided updates on its T cell receptor (TCR) therapies for cancer treatment, including ongoing clinical trials for hematologic malignancies and solid tumors.
TScan Therapeutics, a clinical-stage biotechnology company, announced updates from its PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials, and plans to file an IND application for TSC-102-A0301 (CD45; HLA-A*03:01) with the FDA.
